Fundraising FoxCheckmate Pharmaceuticals
AcquiredCambridge, US · Founded 2015 · 6 known investors
Find your way into Checkmate Pharmaceuticals
Sign up to find every way you can get introduced to Checkmate Pharmaceuticals
- Your email: who you already know at Checkmate Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Checkmate Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Acquired by Regeneron Pharmaceuticals April 2022 · $250M ($250 million all-cash, $10.50 per share) · source ↗
Activating the immune system to recognize and destroy tumor cells. (NASDAQ: CMPI) (Acquired by Regeneron)
Founders & leadership
Checkmate Pharmaceuticals was founded in 2015 by Art Krieg.
AK
Art KriegFounder
BL
Barry LabingerExecutive
CA
Chuck AbdalianExecutive
DM
David MauroExecutive
KB
Karen BrennanExecutive
CY
Charles YonExecutive
Board
BA
Ben AuspitzBoard director
MP
Michael PowellBoard director
CG
Corey GoodmanBoard director
Investors · 6
Decheng Capitallisted by Decheng CapitalMenlo Park
How we know: Decheng Capital's portfolio page · Not right? Tell us
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10Mvia Robert Weisskoff · board
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · Not right? Tell us
Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M
How we know: Longitude Capital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Novo HoldingsreportedCopenhagen · $1.1M – $54M
How we know: funding news · Not right? Tell us
venBio PartnersreportedSan Francisco
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$185.1M disclosed across 6 rounds · 2015–2020
▶$85.1MraisedJun 2020 · 17 investors · BiotechnologyRule 506(b)
▶$85.1MraisedJun 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James WooldridgeExecutive Officer
- Karen BrennanExecutive Officer
- Kleem ChaudharyExecutive Officer
- Robert WeisskoffDirector
- Jonathan LieberExecutive Officer
- Michael PowellDirector
- Barry LabingerExecutive Officer, Director
- Corey GoodmanDirector
- Peter ColabuonoDirector
- Keith FlahertyDirector
- Charles YonExecutive Officer
- Alan FuhrmanDirector
- Arthur KriegExecutive Officer, Director
- Offering amount
- $100.1M
- Amount sold
- $85.1M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$10MraisedApr 2020 · 4 investors · BiotechnologyRule 506(b)
▶$10MraisedApr 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles YonExecutive Officer
- James WooldridgeExecutive Officer
- Jonathan LieberExecutive Officer
- Arthur KriegExecutive Officer, Director
- Barry LabingerExecutive Officer, Director
- Keith FlahertyDirector
- Michael PowellDirector
- Corey GoodmanDirector
- Kleem ChaudharyExecutive Officer
- Alan FuhrmanDirector
- Karen BrennanExecutive Officer
- Peter ColabuonoDirector
- Robert WeisskoffDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$16MraisedJan 2020 · 4 investors · BiotechnologyRule 506(b)
▶$16MraisedJan 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry LabingerExecutive Officer, Director
- Arthur KriegExecutive Officer, Director
- Robert WeisskoffDirector
- Jonathan LieberExecutive Officer
- Karen BrennanExecutive Officer
- James WooldridgeExecutive Officer
- Kleem ChaudharyExecutive Officer
- Charles YonExecutive Officer
- Michael PowellDirector
- Corey GoodmanDirector
- Keith FlahertyDirector
- Alan FuhrmanDirector
- Peter ColabuonoDirector
- Offering amount
- $16M
- Amount sold
- $16M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$22MraisedApr 2019 · 4 investors · BiotechnologyRule 506(b)
▶$22MraisedApr 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry LabingerExecutive Officer, Director
- Ben AuspitzDirector
- Art KriegExecutive Officer, Director
- Chuck AbdalianExecutive Officer
- David MauroExecutive Officer
- Karen BrennanExecutive Officer
- Charles YonExecutive Officer
- Michael PowellDirector
- Corey GoodmanDirector
- Offering amount
- $22M
- Amount sold
- $22M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$27MraisedJun 2017 · 3 investors · BiotechnologyRule 506(b)
▶$27MraisedJun 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Corey GoodmanDirector
- David MauroExecutive Officer
- Ben AuspitzDirector
- Michael PowellDirector
- Charles YonExecutive Officer
- Charles AbdalianExecutive Officer
- Arthur M. KriegExecutive Officer, Director
- Ramani VaranasiExecutive Officer
- Offering amount
- $27M
- Amount sold
- $27M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$25MraisedFeb 2017 · 2 investors · BiotechnologyRule 506(b)
▶$25MraisedFeb 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Corey GoodmanDirector
- Arthur A. KriegExecutive Officer, Director
- Michael PowellDirector
- Chuck AbdalianExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Checkmate Pharmaceuticals do?
- Activating the immune system to recognize and destroy tumor cells. (NASDAQ: CMPI) (Acquired by Regeneron)
- Who founded Checkmate Pharmaceuticals?
- Checkmate Pharmaceuticals was founded by Art Krieg in 2015.
- Who are Checkmate Pharmaceuticals's investors?
- Checkmate Pharmaceuticals's investors include Decheng Capital, F-Prime Capital, Longitude Capital, Sofinnova Ventures, Novo Holdings, venBio Partners.
- How much funding has Checkmate Pharmaceuticals raised?
- Checkmate Pharmaceuticals has disclosed $185.1M raised across 6 rounds.
- Where is Checkmate Pharmaceuticals headquartered?
- Checkmate Pharmaceuticals is headquartered in Cambridge, US.